AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
Flutemetamol (18F) 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4301 | 765922-62-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
used for PET imaging of brain fibrillar amyloid beta
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.077 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.817 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 37.154 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 146.893 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 0.690 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.360 | % | High | 1 |
| herg | hERG pIC50 | 4.488 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 812.831 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 61.802 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 0.720 | % | High | 1 |
| kinase-safety-class | ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK2,CDK5,CDK9,CHEK1,CLK4,CSF1R,DDR1,DYRK1A,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PRKAA1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TNIK,TTK,UHMK1,ULK1,ULK2,ZAP70 | 83 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,BRAF,CAMK2D,DYRK1B,GRK2,MAP2K6,MAP3K21,MAPK7,PDK4,PIK3CA,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,STK33,TTK,ULK1 | 19 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 6.577 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 202.302 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 1.610 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.294 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 3.180 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 271.644 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 15.820 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 0.780 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 0.575 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 27, 2017 | PMDA | Nihon Medi-Physics Co Ltd | |
| Oct. 25, 2013 | FDA | GE HEALTHCARE | |
| Aug. 22, 2014 | EMA | GE Healthcare AS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Flushing | 576.36 | 98.90 | 133 | 595 | 88358 | 90539361 |
| Dyspnoea | 137.75 | 98.90 | 85 | 643 | 880870 | 89746849 |
| Back pain | 124.79 | 98.90 | 57 | 671 | 317118 | 90310601 |
| Chest discomfort | 116.53 | 98.90 | 43 | 685 | 138322 | 90489397 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Flushing | 155.60 | 91.27 | 34 | 132 | 36994 | 42584175 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Flushing | 667.59 | 117.17 | 152 | 659 | 104584 | 110483904 |
| Back pain | 176.40 | 117.17 | 74 | 737 | 370922 | 110217566 |
| Dyspnoea | 138.97 | 117.17 | 90 | 721 | 1106782 | 109481706 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V09AX04 | VARIOUS DIAGNOSTIC RADIOPHARMACEUTICALS CENTRAL NERVOUS SYSTEM Other central nervous system diagnostic radiopharmaceuticals |
| FDA MoA | N0000000205 | Radiopharmaceutical Activity |
| MeSH PA | D003287 | Contrast Media |
| MeSH PA | D007202 | Indicators and Reagents |
| MeSH PA | D019275 | Radiopharmaceuticals |
| MeSH PA | D064907 | Diagnostic Uses of Chemicals |
| FDA EPC | N0000177914 | Radioactive Diagnostic Agent |
| CHEBI has role | CHEBI:37336 | radioactive imaging agent |
Related Drugs by ATC class:
V09AX Other central nervous system diagnostic radiopharmaceuticals 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Positron emission tomography | indication | 82918005 | |
| Diagnosis of Alzheimer's disease | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.2 | acidic |
| pKa2 | 3.58 | Basic |
| pKa3 | 2.7 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amyloid beta A4 protein | Membrane other | Ki | 9.15 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D10231 | KEGG_DRUG |
| 4038255 | VANDF |
| C2983948 | UMLSCUI |
| CHEMBL2042122 | ChEMBL_ID |
| DB09151 | DRUGBANK_ID |
| 15950376 | PUBCHEM_CID |
| 1486025 | RXNORM |
| 206870 | MMSL |
| 29778 | MMSL |
| d08135 | MMSL |
| 016452 | NDDF |
| 456996004 | SNOMEDCT_US |
| 456997008 | SNOMEDCT_US |
| CHEBI:76611 | CHEBI |
| 9169 | INN_ID |
| C581552 | MESH_SUPPLEMENTAL_RECORD_UI |
| L49M066S0O | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Vizamyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17156-067 | SOLUTION | 4.05 mCi | INTRAVENOUS | NDA | 28 sections |
| Vizamyl | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17156-067 | SOLUTION | 4.05 mCi | INTRAVENOUS | NDA | 28 sections |